BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:BIO.B • US0905721082
295.05 USD
-17.7 (-5.66%)
Last: Feb 2, 2026, 08:04 PM
BIO.B gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability. BIO.B is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- BIO.B had positive earnings in the past year.
- In the past year BIO.B had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
- Each year in the past 5 years BIO.B had a positive operating cash flow.
1.2 Ratios
- With a Return On Assets value of -6.97%, BIO.B perfoms like the industry average, outperforming 53.45% of the companies in the same industry.
- With a Return On Equity value of -10.03%, BIO.B perfoms like the industry average, outperforming 53.45% of the companies in the same industry.
- The Return On Invested Capital of BIO.B (2.26%) is better than 62.07% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 13.29%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
- BIO.B has a better Operating Margin (10.27%) than 70.69% of its industry peers.
- BIO.B's Operating Margin has been stable in the last couple of years.
- BIO.B has a better Gross Margin (52.42%) than 63.79% of its industry peers.
- BIO.B's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO.B is destroying value.
- The number of shares outstanding for BIO.B has been reduced compared to 1 year ago.
- Compared to 5 years ago, BIO.B has less shares outstanding
- BIO.B has a worse debt/assets ratio than last year.
2.2 Solvency
- BIO.B has an Altman-Z score of 3.33. This indicates that BIO.B is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.33, BIO.B is in the better half of the industry, outperforming 67.24% of the companies in the same industry.
- The Debt to FCF ratio of BIO.B is 3.57, which is a good value as it means it would take BIO.B, 3.57 years of fcf income to pay off all of its debts.
- BIO.B has a better Debt to FCF ratio (3.57) than 77.59% of its industry peers.
- A Debt/Equity ratio of 0.18 indicates that BIO.B is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.18, BIO.B is in line with its industry, outperforming 58.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.33 |
ROIC/WACC0.21
WACC10.74%
2.3 Liquidity
- BIO.B has a Current Ratio of 5.44. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
- BIO.B has a Current ratio of 5.44. This is amongst the best in the industry. BIO.B outperforms 86.21% of its industry peers.
- A Quick Ratio of 3.94 indicates that BIO.B has no problem at all paying its short term obligations.
- The Quick ratio of BIO.B (3.94) is better than 68.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
- BIO.B shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.90%.
- The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
- The Revenue has decreased by -0.88% in the past year.
- Measured over the past years, BIO.B shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
- BIO.B is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.66% yearly.
- BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.26% yearly.
EPS Next Y-2.48%
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
EPS Next 5Y-2.66%
Revenue Next Year0.04%
Revenue Next 2Y1.13%
Revenue Next 3Y1.96%
Revenue Next 5Y1.26%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 28.62 indicates a quite expensive valuation of BIO.B.
- Based on the Price/Earnings ratio, BIO.B is valued a bit cheaper than the industry average as 70.69% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of BIO.B to the average of the S&P500 Index (28.06), we can say BIO.B is valued inline with the index average.
- Based on the Price/Forward Earnings ratio of 28.78, the valuation of BIO.B can be described as expensive.
- Based on the Price/Forward Earnings ratio, BIO.B is valued a bit cheaper than the industry average as 68.97% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of BIO.B to the average of the S&P500 Index (27.86), we can say BIO.B is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.62 | ||
| Fwd PE | 28.78 |
4.2 Price Multiples
- 79.31% of the companies in the same industry are more expensive than BIO.B, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.63 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.65
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
5. Dividend
5.1 Amount
- No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NYSE:BIO.B (2/2/2026, 8:04:00 PM)
295.05
-17.7 (-5.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-12 2026-02-12/amc
Inst Owners92.92%
Inst Owner Change0.28%
Ins Owners8.18%
Ins Owner ChangeN/A
Market Cap7.96B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target363.55 (23.22%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)0%
PT rev (3m)-1.58%
EPS NQ rev (1m)-1.46%
EPS NQ rev (3m)-3.02%
EPS NY rev (1m)-0.55%
EPS NY rev (3m)4.13%
Revenue NQ rev (1m)-0.65%
Revenue NQ rev (3m)-1.79%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.62 | ||
| Fwd PE | 28.78 | ||
| P/S | 3.11 | ||
| P/FCF | 23.63 | ||
| P/OCF | 16.19 | ||
| P/B | 1.18 | ||
| P/tB | 1.38 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.49%
EPS(NY)10.25
Fwd EY3.47%
FCF(TTM)12.48
FCFY4.23%
OCF(TTM)18.22
OCFY6.18%
SpS94.83
BVpS249.79
TBVpS213.93
PEG (NY)N/A
PEG (5Y)3.65
Graham Number240.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.33 |
F-Score5
WACC10.74%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-2.48%
EPS Next 2Y-0.29%
EPS Next 3Y3.33%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.04%
Revenue Next 2Y1.13%
Revenue Next 3Y1.96%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.36%
EBIT Next 3Y14.58%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 3 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Overvalued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 4 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 7 / 10.